GleamWall
中文EN

ARTL ARTELO BIOSCIENCES, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1621221 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY9.4%
TTM EPS YoY188.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-404.2%
ROA-206.9%
ROIC (approx.)-398.3%
Asset turnover—

Leverage & solvency

Liabilities / assets6.6%
Debt / equity0.00x
Current ratio10.47x
Interest coverage-83.52x

Cash quality & payout

Operating cash flow / net income1.04x
Accruals ratio8.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$5.42M$5.99M
SG&A expense$5.98M$4.12M
Operating income-$11.40M-$10.11M
Interest expense$194,000$0
Income tax$0$0
Net income-$12.88M-$9.83M
EPS (diluted)-12.52-18.30
Weighted avg. shares (diluted)1.03M537,000
Balance sheet
Cash & equivalents$600,000$2.34M
Short-term investments—$0
Current assets$695,000$2.56M
Intangibles$2.04M$2.04M
Total assets$2.80M$4.70M
Current liabilities$4.04M$1.77M
Total liabilities$4.07M$1.84M
Shareholders' equity-$1.27M$2.86M
Shares outstanding74,779567,582
Cash flow statement
Operating cash flow-$8.52M-$8.35M
Investing cash flow-$62,000$7.77M
Financing cash flow$6.87M$112,000
Stock-based compensation$1.14M$818,000

Free plan shows the latest 2 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.